Deferiprone, an iron chelator (binder) therapy, does not slow the progression of Parkinson’s disease in newly diagnosed patients who have never received treatment, according to data from a Phase 2 clinical trial. Instead, after about nine months of treatment in these patients, deferiprone was associated with a worsening of…
Blood levels of small vesicles originating in neurons and containing proteins related to Parkinson’s disease or Alzheimer’s disease — alpha-synuclein, phosphorylated tau, or insulin receptor substrate 1 (IRS-1) — can be biomarkers of cognitive impairment in Parkinson’s patients, a study reported. Changes in the levels of vesicles carrying these…
Levels of neurofilament light chain (NfL) protein in the bloodstream of people with Parkinson’s disease can independently predict cognitive decline, a recent study suggests. Although p-tau181 concentration, a biomarker in Alzheimer’s disease, which is the most common cause of dementia, was higher in Parkinson’s patients, links to cognitive performance…
Difficulty in swallowing medications, either tablets or capsules, was common among people with Parkinson’s disease, a study reports. This impairment in swallowing, called dysphagia, also predicted worse motor complications, and data suggest capsules tended to be easier to swallow than tablets. Evidence of swallowing difficulties for food is a…
Toxic clumps of the alpha-synuclein protein, the underlying cause of neurodegeneration in Parkinson’s disease, may originate in the digestive tract before migrating to the brain, a study in mice reported, supporting previous work into a gut-brain axis in disease development. Changes to microbes in the digestive tract, known…
Swallowing difficulties in people with Parkinson’s disease are associated with the dysfunction of nerves that supply the heart muscle as part of the autonomic, or involuntary, nervous system, a study revealed. The noninvasive method to measure this dysfunction, called cardiac MIBG scintigraphy, could help identify Parkinson’s patients who may…
Alpha-synuclein protein clumps — the toxic aggregates related to nerve damage in Parkinson’s disease — vary, including in size, and small fragments appear to drive cellular toxicity compared with larger fragments, a study shows. Its findings were confirmed in post-mortem examinations of brain tissue from Parkinson’s patients, showing smaller clumps…
Fifty new genes that modified signs of Parkinson’s disease in a fruit fly model have been discovered using a multidisciplinary approach involving genomics, computational tools, and patient sample analysis, a study has reported. Some gene candidates worsened Parkinson’s signs while others conferred neuroprotection, “underscoring their therapeutic potential,” the researchers…
A Phase 1/2a clinical trial testing the ability of AMDX-2011P to safely detect abnormal protein deposits in the retina of adults with Parkinson’s disease and amyotrophic lateral sclerosis (ALS), possibly allowing earlier diagnosis and easier patient monitoring, has dosed its first participants. These proteins comprise alpha-synuclein in Parkinson’s…
Clumps of alpha-synuclein protein, which build to toxic levels in the brain and spinal cord of Parkinson’s disease patients, spread via a cellular waste-ejection process, according to a study in mice. These clumps, which failed to be broken down in lysosomes, the cells’ recycling centers, are released by nerve…
Get regular updates to your inbox.
